Pablo Fernandez Penas

List of Publications by Year
in descending order

200	6,298	81900 39	79698 73
papers	citations	h-index	g-index

207	207	207	6010
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. Journal of the American Academy of Dermatology, 2008, 58, 375-381.	1.2	785
2	A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. New England Journal of Medicine, 2015, 373, 1618-1626.	27.0	469
3	Sentinel Lymph Node Biopsy for Evaluation and Treatment of Patients With Merkel Cell Carcinoma. Archives of Dermatology, 2006, 142, 685-90.	1.4	333
4	Bed Bugs: Clinical Relevance and Control Options. Clinical Microbiology Reviews, 2012, 25, 164-192.	13.6	272
5	Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. Journal of the American Academy of Dermatology, 2016, 74, 455-461.e1.	1.2	247
6	Cutaneous toxicities of RAF inhibitors. Lancet Oncology, The, 2013, 14, e11-e18.	10.7	190
7	Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. British Journal of Dermatology, 2012, 167, 1153-1160.	1.5	163
8	Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatology, 2015, 151, 1103.	4.1	139
9	A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Research, 2015, 25, 265-268.	1.2	116
10	Array-CGH Reveals Recurrent Genomic Changes in Merkel Cell Carcinoma Including Amplification of L-Myc. Journal of Investigative Dermatology, 2009, 129, 1547-1555.	0.7	113
11	Diagnostic and neural analysis of skin cancer (DANAOS). A multicentre study for collection and computer-aided analysis of data from pigmented skin lesions using digital dermoscopy. British Journal of Dermatology, 2003, 149, 801-809.	1.5	112
12	Toxic Epidermal Necrolysisâ€“like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma. Journal of Immunotherapy, 2016, 39, 149-152.	2.4	104
13	Tetraspanins are Localized at Motility-Related Structures and Involved in Normal Human Keratinocyte Wound Healing Migration. Journal of Investigative Dermatology, 2000, 114, 1126-1135.	0.7	98
14	Sclerodermatous Graft-vs-Host Disease. Archives of Dermatology, 2002, 138, 924-34.	1.4	92
15	Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Research, 2016, 26, 413-416.	1.2	75
16	Perforating granuloma annulare. International Journal of Dermatology, 1997, 36, 340-348.	1.0	70
17	Quality of life in mild to moderate acne: relationship to clinical severity and factors influencing change with treatment. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 219-226.	2.4	66
18	The Spanish version of Skindexâ€29. International Journal of Dermatology, 2000, 39, 907-912.	1.0	65

#	Article	IF	Citations
19	Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelinesâ¨†. Annals of Oncology, 2021, 32, 157-170.	1.2	65
20	Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib. Australasian Journal of Dermatology, 2014, 55, 250-254.	0.7	60
21	Leishmaniasis presenting as a dermatomyositis-like eruption in AIDS. Journal of the American Academy of Dermatology, 1996, 35, 316-319.	1.2	56
22	A Polypodium leucotomos extract inhibits solarâ€simulated radiationâ€induced TNFâ€Î± and iNOS expression, transcriptional activation and apoptosis. Experimental Dermatology, 2007, 16, 823-829.	2.9	56
23	Quality of life in nonâ€melanoma skin cancer. Australasian Journal of Dermatology, 2015, 56, 70-76.	0.7	56
24	Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study. Journal of the American Academy of Dermatology, 2018, 79, 824-830.e2.	1.2	55
25	Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events. Journal of the American Academy of Dermatology, 2020, 82, 311-316.	1.2	55
26	Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell and Melanoma Research, 2012, 25, 569-572.	3.3	53
27	Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in <scp>A</scp>ustralia. Australasian Journal of Dermatology, 2016, 57, 167-174.	0.7	53
28	Panniculitis in Patients Treated With BRAF Inhibitors. American Journal of Dermatopathology, 2014, 36, 493-497.	0.6	52
29	Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis. British Journal of Dermatology, 2012, 166, 884-887.	1.5	50
30	Mechanism of mannose toxicity. Biochemical and Biophysical Research Communications, 1986, 140, 51-55.	2.1	48
31	Role of Tetraspanins CD9 and CD151 in Primary Melanocyte Motility. Journal of Investigative Dermatology, 2005, 125, 1001-1009.	0.7	46
32	Many faces of graftâ€versusâ€host disease. Australasian Journal of Dermatology, 2010, 51, 1-10.	0.7	46
33	The microbiome and atopic eczema: More than skin deep. Australasian Journal of Dermatology, 2017, 58, 18-24.	0.7	46
34	Alopecia syphilitica with detection of Treponema pallidum in the hair follicle. Journal of Cutaneous Pathology, 2007, 34, 37-40.	1.3	45
35	Self-Reported Adherence to Treatment and Quality of Life in Mild to Moderate Acne. Dermatology, 2008, 217, 309-314.	2.1	43
36	Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52Âweeks. British Journal of Dermatology, 2015, 172, 239-243.	1.5	43

#	Article	IF	Citations
37	Patient perceptions of clear/almost clear skin in moderateâ€toâ€severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2200-2207.	2.4	42
38	Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. British Journal of Dermatology, 2013, 169, 1310-1313.	1.5	41
39	PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. Melanoma Research, 2016, 26, 421-424.	1.2	40
40	Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. Journal of the American Academy of Dermatology, 2015, 72, 809-815.e1.	1.2	39
41	Association of Helicobacter pylori Infection With Psoriasis and Lichen Planus: Prevalence and Effect of Eradication Therapy. Archives of Dermatology, 2000, 136, 1275-1276.	1.4	38
42	Dermatologic Treatment of Cutaneous Graft Versus Host Disease. American Journal of Clinical Dermatology, 2004, 5, 403-416.	6.7	37
43	Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma. Melanoma Research, 2016, 26, 417-420.	1.2	37
44	Vitiligoâ€like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. Clinical and Experimental Dermatology, 2019, 44, 643-646.	1.3	36
45	AnÃ¡lisis de los diagnÃ³sticos realizados en la actividad ambulatoria dermatolÃ³gica en EspaÃ±a: muestreo aleatorio nacional DIADERM. Actas Dermo-sifiliogrÃ¡ficas, 2018, 109, 416-423.	0.4	33
46	Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. British Journal of Dermatology, 2018, 178, 715-721.	1.5	33
47	Maculopapular eruption with enlarged macrophages in eight patients receiving Gâ€CSF or GMâ€CSF. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 310-313.	2.4	31
48	Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 6-16.	0.4	31
49	Cutaneous meningioma underlying congenital localized hypertrichosis. Journal of the American Academy of Dermatology, 1994, 30, 363-366.	1.2	29
50	Differential Expression of Activation Epitopes of Î²1 Integrins in Psoriasis and Normal Skin. Journal of Investigative Dermatology, 1998, 111, 19-24.	0.7	29
51	Solar-Simulated Ultraviolet Radiation Induces Abnormal Maturation and Defective Chemotaxis of Dendritic Cells. Journal of Investigative Dermatology, 2005, 125, 334-342.	0.7	29
52	Systemic Retinoid Therapy for Chemoprevention of Nonmelanoma Skin Cancer in a Patient Treated With Vemurafenib. Journal of Clinical Oncology, 2012, 30, e165-e167.	1.6	29
53	Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Deathâ€“1 (antiâ€“PD-1) Therapy With or Without Ipilimumab. American Journal of Dermatopathology, 2017, 39, 23-27.	0.6	28
54	Treatment of face and scalp solar (actinic) keratosis with daylightâ€mediated photodynamic therapy is possible throughout the year in A ustralia: Evidence from a clinical and meteorological study. Australasian Journal of Dermatology, 2016, 57, 24-28.	0.7	27

#	Article	IF	Citations
55	Association Between Melanoma Detected During Routine Skin Checks and Mortality. JAMA Dermatology, 2021, 157, 1425.	4.1	27
56	Differential proteomic analysis of actinic keratosis, Bowenâ€™s disease and cutaneous squamous cell carcinoma by label-free LCâ€“MS/MS. Journal of Dermatological Science, 2018, 91, 69-78.	1.9	26
57	Atypical fibroxanthoma management: Recurrence, metastasis and diseaseâ€specific death. Australasian Journal of Dermatology, 2018, 59, 10-25.	0.7	26
58	D - Penicillamine-induced pemphigus foliaceus with autoantibodies to desmoglein-1 in a patient with mixed connective tissue disease. Journal of the American Academy of Dermatology, 1997, 37, 121-123.	1.2	25
59	Efficiency of Detecting New Primary Melanoma Among Individuals Treated in a High-risk Clinic for Skin Surveillance. JAMA Dermatology, 2021, 157, 521.	4.1	25
60	Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2184-2191.	2.4	24
61	Recall phenomenon with the unusual presence of eccrine squamous syringometaplasia. British Journal of Dermatology, 1995, 133, 630-632.	1.5	23
62	Sun Exposure Habits and Sun Protection Practices of Skaters. Journal of Cancer Education, 2017, 32, 734-739.	1.3	23
63	Lichen Planus-Like Drug Eruptions Due to Î²-Blockers. American Journal of Clinical Dermatology, 2012, 13, 417-421.	6.7	22
64	Behaviour, attitudes and awareness concerning sun exposure in adolescents on the Costa del sol. European Journal of Dermatology, 2014, 24, 85-93.	0.6	22
65	Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. Melanoma Research, 2015, 25, 91-94.	1.2	22
66	Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab). Current Problems in Dermatology, 2018, 53, 82-92.	0.7	22
67	Data Independent Acquisition Proteomic Analysis Can Discriminate between Actinic Keratosis, Bowenâ€™s Disease, and Cutaneous Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2020, 140, 212-222.e11.	0.7	22
68	PDâ€1 inhibitorâ€associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculationâ€”Report of 4 cases. Journal of Cutaneous Pathology, 2017, 44, 851-856.	1.3	21
69	A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia . Drug Design, Development and Therapy, 2020, Volume 14, 1177-1189.	4.3	21
70	Eosinophilic folliculitis following allogeneic peripheral blood stem cell transplantation: case report and review. Journal of Cutaneous Pathology, 2007, 34, 33-36.	1.3	19
71	Direct Cost-Analysis of Mohs Micrographic Surgery and Traditional Excision for Basal Cell Carcinoma at Initial Margin Clearance. Dermatologic Surgery, 2016, 42, 633-638.	0.8	19
72	Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature. Melanoma Research, 2018, 28, 491-501.	1.2	19

#	Article	IF	Citations
73	Keratosis punctata of the Palmar Creases: Case Report and Prevalence Study in Caucasians. Dermatology, 1994, 188, 200-202.	2.1	18
74	Use of Biological Agents in Patients With Moderate to Severe Psoriasis. Archives of Dermatology, 2007, 143, 846-50.	1.4	18
75	Pseudoxanthoma elasticum-like papillary dermal elastolysis. A report of two cases and review of the literature.. Acta Dermato-Venereologica, 1997, 77, 43-45.	1.3	18
76	Pachyonychia congenita and hidradenitis suppurativa: no response to infliximab therapy. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 1500-1501.	2.4	17
77	Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies. Dermatology and Therapy, 2021, 11, 971-982.	3.0	17
78	Cutaneous lichenoid graft-versus-host disease mimicking lupus erythematosus. Lupus, 2008, 17, 591-595.	1.6	16
79	Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007). Journal of the American Academy of Dermatology, 2010, 63, 832-835.	1.2	16
80	Objective severity does not capture the impact of rosacea, acne scarring and photoaging in patients seeking laser therapy. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 361-366.	2.4	16
81	Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7. Dermatology and Therapy, 2021, 11, 1599-1611.	3.0	16
82	Reticular Erythematous Mucinosis Associated with Human Immunodeficiency Virus Infection. Dermatology, 1995, 191, 157-160.	2.1	15
83	Pustular acral erythema in a patient with acute graft-versus-host disease. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 550-553.	2.4	15
84	Squamous cell carcinoma arising in a recent plaque of discoid lupus erythematous, in a sun-protected area. Lupus, 2010, 19, 210-212.	1.6	15
85	Classification of high risk basal cell carcinoma subtypes: experience of the ONTRAC study with proposed definitions and guidelines for pathological reporting. Pathology, 2016, 48, 395-397.	0.6	15
86	Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma. Melanoma Research, 2019, 29, 172-177.	1.2	15
87	In Silico Analysis Validates Proteomic Findings of Formalin-fixed Paraffin Embedded Cutaneous Squamous Cell Carcinoma Tissue. Cancer Genomics and Proteomics, 2016, 13, 453-466.	2.0	15
88	Malignant melanoma appearing in a seborrhoeic keratosis. British Journal of Dermatology, 1995, 133, 1016-1018.	1.5	14
89	Phototherapy for the treatment of cutaneous graft versus host disease. Australasian Journal of Dermatology, 2015, 56, 93-99.	0.7	14
90	Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 6-16.	0.4	14

#	Article	IF	Citations
91	Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2149-2153.	2.4	14
92	Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils. Melanoma Research, 2017, 27, 641-644.	1.2	14
93	Systemic and erythrodermic reactions following repeated exposure to bites from the Common bed bug Cimex lectularius (Hemiptera: Cimicidae). Austral Entomology, 2017, 56, 345-347.	1.4	13
94	DerivaciÃ³n de pacientes en consulta de dermatologÃa y de teledermatologÃa en EspaÃ±a. Estudio DIADERM. Actas Dermo-sifiliogrÃ¡ficas, 2019, 110, 146-152.	0.4	13
95	The clinical and histologic spectrum of chronic graft-versus-host disease. Journal of the American Academy of Dermatology, 2006, 55, 729.	1.2	12
96	Stage IV cutaneous acute graft-versus-host disease. Clinical and histological study of 15 cases. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1398-1404.	2.4	12
97	Rational use of topical corticosteroids. Australian Prescriber, 2013, 36, 159-161.	1.0	12
98	A Follicular Lichenoid Eruption as Manifestation of Chronic Graft-vs-Host Disease. Acta Dermato-Venereologica, 1998, 78, 386-386.	1.3	11
99	Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy. Melanoma Research, 2014, 24, 501-503.	1.2	11
100	Patch Testing for Cheilitis: A 10-Year Series. Dermatitis, 2019, 30, 347-351.	1.6	11
101	Prevalence of skin examination behaviours among Australians over time. Cancer Epidemiology, 2021, 70, 101874.	1.9	11
102	Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib. Australasian Journal of Dermatology, 2017, 58, 69-70.	0.7	10
103	Tape Stripped Stratum Corneum Samples Prove to be Suitable for Comprehensive Proteomic Investigation of Actinic Keratosis. Proteomics - Clinical Applications, 2019, 13, 1800084.	1.6	10
104	Proteomics: An emerging approach for the diagnosis and classification of cutaneous squamous cell carcinoma and its precursors. Journal of Dermatological Science, 2020, 99, 9-16.	1.9	10
105	Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1949-1956.	2.4	10
106	Time-Dependent Measurement of Adverse Events. JAMA Dermatology, 2015, 151, 1392.	4.1	9
107	Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study. Australasian Journal of Dermatology, 2017, 58, 292-298.	0.7	9
108	Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma. Journal of Immunotherapy, 2018, 41, 343-349.	2.4	9

#	Article	IF	Citations
109	Systematic review and proposal of an in vivo reflectance confocal microscopy assessment tool for cutaneous lymphoma. Journal of Cutaneous Pathology, 2020, 47, 295-304.	1.3	9
110	Investigating proteome changes between primary and metastatic cutaneous squamous cell carcinoma using SWATH mass spectrometry. Journal of Dermatological Science, 2020, 99, 119-127.	1.9	9
111	Dermatology inpatient consultations in a tertiary hospital â€“ a retrospective analysis. International Journal of Dermatology, 2022, 61, 48-53.	1.0	9
112	Uncovering the unmet needs among psoriasis patients in the Asiaâ€Pacific region. Journal of Dermatology, 2021, 48, 1665-1674.	1.2	9
113	AnÃ¡lisis de la proporciÃ³n de derivaciones potencialmente evitables desde AtenciÃ³n Primaria a DermatologÃa por lesiones quÃsticas o tumorales benignas en EspaÃ±a. Datos del estudio DIADERM. Actas Dermo-sifiliogrÃ¡ficas, 2019, 110, 659-665.	0.4	9
114	Condyloma-like lesions as the presenting sign of multiple Myeloma associated amyloidosis. British Journal of Dermatology, 1996, 135, 665-666.	1.5	8
115	O'Brien actinic granuloma presenting as alopecia. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 226-227.	2.4	8
116	BRAF Inhibitor Induced Verrucal Keratosis. American Journal of Dermatopathology, 2014, 36, 192.	0.6	8
117	Dabrafenib-associated necrobiotic granulomatous reaction. Australasian Journal of Dermatology, 2014, 55, 306-308.	0.7	8
118	Factors affecting choice of repair in Mohs micrographic surgery for nonâ€melanoma skin cancer of the head. Australasian Journal of Dermatology, 2017, 58, 189-193.	0.7	8
119	Outpatient Dermatological Diagnoses in Spain: Results From the National DIADERM Random Sampling Project. Actas Dermo-sifiliogrÃ¡ficas, 2018, 109, 416-423.	0.4	8
120	Cutaneous lesions as the first sign of disseminated mucormycosis.. Acta Dermato-Venereologica, 1995, 75, 166-167.	1.3	8
121	Cutaneous epithelioid angiosarcoma occurring at a peristomal site. Journal of the American Academy of Dermatology, 2010, 63, e55-e56.	1.2	7
122	Mechanisms of BRAFiâ€induced hyperproliferative cutaneous conditions. Experimental Dermatology, 2016, 25, 394-395.	2.9	7
123	Scar outcomes in dermatological surgery. Australasian Journal of Dermatology, 2018, 59, 48-51.	0.7	7
124	Atypical Early Follicular Graft-vs-Host Disease. Archives of Dermatology, 2006, 142, 1231.	1.4	7
125	Â¿Existe variaciÃ³n en los diagnÃ³sticos dermatolÃ³gicos entre la temporada de frÃo vs. calor? Un subanÃ¡lisis del estudio DIADERM (EspaÃ±a 2016). Actas Dermo-sifiliogrÃ¡ficas, 2019, 110, 734-743.	0.4	7
126	Lichen amyloidosus and Human Immunodeficiency Virus Infection. Dermatology, 1995, 191, 56-58.	2.1	6

#	Article	IF	Citations
127	A severe case of pachyonychia congenita type I due to a novel proline mutation in keratin 6a. British Journal of Dermatology, 2005, 152, 800-802.	1.5	6
128	Hidradenitis Suppurativa. Response to Treatment With Infliximab. Actas Dermo-sifiliogrÃ¡ficas, 2007, 98, 325-331.	0.4	6
129	An analysis of the dermatological uses of mycophenolate mofetil in a tertiary hospital. Journal of Dermatological Treatment, 2015, 26, 63-66.	2.2	6
130	Why do young adults tan?. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e259-e261.	2.4	6
131	Epidermal growth factor receptor inhibitorâ€induced papulopustular eruption successfully treated with lowâ€dose oral dapsone. Australasian Journal of Dermatology, 2018, 59, e219-e220.	0.7	6
132	Â¿CuÃ¡nta carga asistencial suponen las infecciones de transmisiÃ³n predominantemente sexual y otras dermatosis anogenitales en las consultas de DermatologÃa en EspaÃ±a? Resultados del muestreo aleatorio nacional DIADERM. Actas Dermo-sifiliogrÃ¡ficas, 2022, 113, 22-29.	0.4	6
133	Diffuse melanosis cutis in the setting of <scp>BRAF</scp>^{V600E} mutant melanoma and treatment with targeted therapies. Australasian Journal of Dermatology, 2015, 56, 128-130.	0.7	5
134	Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors). Medical Journal of Australia, 2017, 206, 412-412.	1.7	5
135	Management of the cutaneous adverse effects of antimelanoma therapy. Melanoma Management, 2017, 4, 187-202.	0.5	5
136	Problemas de la CIE-10 para la codificaciÃ³n de diagnÃ³sticos dermatolÃ³gicos. Estudio DIADERM. Actas Dermo-sifiliogrÃ¡ficas, 2018, 109, 893-899.	0.4	5
137	Incidence of cardiovascular events among tildrakizumabâ€treated patients with moderateâ€toâ€severe plaque psoriasis: pooled data from three large randomised clinical trials. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e21-e24.	2.4	5
138	Allergic Contact Dermatitis of the Anogenital Region in Men and Women. Journal of Lower Genital Tract Disease, 2020, 24, 221-224.	1.9	5
139	Cutaneous T-cell lymphoma and myelodysplastic syndrome. Journal of the American Academy of Dermatology, 1994, 31, 1065-1067.	1.2	4
140	Implication of MT1-MMP in the maturation steps of benign melanocytic nevi. Journal of Cutaneous Pathology, 2006, 33, 139-144.	1.3	4
141	Acute severe form of lichenoid graft-versus-host disease after donor lymphocyte infusions. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 632-634.	2.4	4
142	Tinea hidden by a vemurafenibâ€induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone. Medical Journal of Australia, 2015, 203, 41-42.	1.7	4
143	Treatment-specific utility weightings are needed for cost-utility analysis in metastatic melanoma. British Journal of Dermatology, 2016, 174, 462-463.	1.5	4
144	Transient acantholytic dyskeratosis (Grover's disease) after bone marrow transplantation. Australasian Journal of Dermatology, 2016, 57, e120-e122.	0.7	4

#	Article	IF	Citations
145	FR - Nuevas indicaciones de nicotinamida en dermatologÃa. Actas Dermo-sifiliogrÃ¡ficas, 2016, 107, 777-778.	0.4	4
146	Self-directed tablet education session improves safety knowledge among patients undergoing phototherapy. British Journal of Dermatology, 2017, 176, 1382-1384.	1.5	4
147	The efficacy and safety of methotrexate versus interferon in cutaneous T-cell lymphomas. Journal of Dermatological Treatment, 2018, 29, 715-719.	2.2	4
148	Mohs Micrographic Surgery at the Skin and Cancer Foundation Australia, 20 Years Later (1997â€“2017). Dermatologic Surgery, 2020, 46, 165-168.	0.8	4
149	Reflectance confocal microscopy as a new diagnostic tool in transformed mycosis fungoides. Australasian Journal of Dermatology, 2020, 61, e358-e363.	0.7	4
150	Merkel cell carcinoma in situ: A systematic review of prognosis and management. Australasian Journal of Dermatology, 2022, 63, .	0.7	4
151	Erythema ab igne as a differential diagnosis of chronic graft versus host disease (GVHD). International Journal of Dermatology, 2012, 51, 1226-1227.	1.0	3
152	Lack of efficacy of rituximab in refractory sclerodermatous chronic GVHD. Bone Marrow Transplantation, 2012, 47, 737-738.	2.4	3
153	Cutaneous nonâ€tuberculous mycobacterial infection in patients with chronic graftâ€versusâ€host disease: A case series. Australasian Journal of Dermatology, 2015, 56, 124-127.	0.7	3
154	Experience of skin cancer and contact with health professionals is associated with increased skin cancer knowledge, but not sun safety knowledge or behaviour. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e338-e340.	2.4	3
155	Is it worthy to treat hidradenitis suppurativa with adalimumab in patients with melanoma and other debilitating systemic diseases? A series of clinical dilemmas. Australasian Journal of Dermatology, 2018, 59, e297-e298.	0.7	3
156	Management of cutaneous Tâ€cell lymphomas: Established and emergent therapies. Australasian Journal of Dermatology, 2019, 60, 200-208.	0.7	3
157	Keratinocyte carcinoma as a chronic disease in Australia and Spain: The importance of avoidance of perceived visible scars. Australasian Journal of Dermatology, 2019, 60, 284-287.	0.7	3
158	Neurocognitive Function and Quality of Life Outcomes in the ONTRAC Study for Skin Cancer Chemoprevention by Nicotinamide. Geriatrics (Switzerland), 2019, 4, 31.	1.7	3
159	Reflectance confocal microscopy role in mycosis fungoides followâ€up. Skin Research and Technology, 2021, 27, 414-421.	1.6	3
160	Â¿CuÃ¡nta carga asistencial supone la enfermedad tumoral cutÃ¡nea en la actividad ambulatoria en la DermatologÃa espaÃ±ola? Resultados del muestreo aleatorio nacional DIADERM. Actas Dermo-sifiliogrÃ¡ficas, 2021, 112, 632-639.	0.4	3
161	Mass spectrometryâ€based proteomic analysis of the effect of storage temperature on nonâ€invasively collected samples of human stratum corneum. Proteomics - Clinical Applications, 2021, 15, 2100005.	1.6	3
162	Specialised skin cancer spectral library for use in dataâ€independent mass spectrometry. Proteomics, 2021, 21, e2100128.	2.2	3

#	Article	IF	Citations
163	Stellate hypopigmented macules and papules on photoexposed areas. Clinical and Experimental Dermatology, 2007, 32, 337-338.	1.3	2
164	Gemcitabine and vinorelbine treatment in cutaneous <scp>T</scp>â€cell lymphoma in four patients. Australasian Journal of Dermatology, 2015, 56, 294-297.	0.7	2
165	Nicotinamide: New Indications in Dermatology. Actas Dermo-sifiliogrÃ¡ficas, 2016, 107, 777-778.	0.4	2
166	Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis. Case Reports in Medicine, 2017, 2017, 1-3.	0.7	2
167	Cutaneous nonâ€tuberculous mycobacteria in Western Sydney, Australia. Population study 1996â€“2013. Australasian Journal of Dermatology, 2018, 59, 343-345.	0.7	2
168	Public body consciousness is associated with positive tanning attitudes and behaviours regardless of gender or age. Australasian Journal of Dermatology, 2019, 60, 250-251.	0.7	2
169	Tanning, selfies and social media. Australasian Journal of Dermatology, 2019, 60, 82-84.	0.7	2
170	Successful treatment of highly refractory necrobiotic xanthogranuloma with peginterferon alfaâ€2a. Clinical and Experimental Dermatology, 2021, 46, 731-733.	1.3	2
171	799â€...Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data. , 2020, , .		2
172	Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (<scp>MelCOR</scp>): A modified Delphi study. Australasian Journal of Dermatology, 2022, , .	0.7	2
173	Perianal Lentiginosis: A Case of Localized Lentiginosis. Acta Dermato-Venereologica, 2003, 83, 379-380.	1.3	1
174	Las cabinas de bronceado, el cÃ¡ncer de piel, los estÃ¡ndares internacionales y la funciÃ³n social del dermatÃ³logo. Actas Dermo-sifiliogrÃ¡ficas, 2008, 99, 429-430.	0.4	1
175	Potent topical steroids are one of the treatments for cutaneous T-cell lymphoma. Journal of Allergy and Clinical Immunology, 2010, 126, 414.	2.9	1
176	Cutaneous Nodules in the Genital Area in a Patient With Chronic Graft-vs-Host Disease. JAMA Dermatology, 2017, 153, 465.	4.1	1
177	Naevus lightening in melanoma patients under <scp>BRAF</scp>/<scp>MEK</scp> inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis. Pigment Cell and Melanoma Research, 2018, 31, 341-344.	3.3	1
178	Use of immortal time within survival analysis. Journal of the American Academy of Dermatology, 2019, 80, e17.	1.2	1
179	Risk Perception Plays Minimal Role in Sun Exposure Behaviours. Journal of Cancer Education, 2020, 35, 125-130.	1.3	1
180	Adherence to suggestions after dermatology consultation in a tertiary hospital â€“ a retrospective analysis. Australasian Journal of Dermatology, 2021, 62, e582-e585.	0.7	1

#	Article	IF	Citations
181	Toxic epidermal necrolysisâ€like lupus erythematosus: a condition to exclude in all patients with possible Stevensâ€Johnson syndrome/toxic epidermal necrolysis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
182	[Translated article] What Proportion of the Spanish Dermatology Caseload Corresponds to Primarily Sexually Transmitted Infections and Other Anogenital Dermatoses? Results From the DIADERM National Random Survey. Actas Dermo-sifiliogrÃ¡ficas, 2022, 113, T22-T29.	0.4	1
183	Treatment of mycosis fungoides with etretinate and low-dose interferon Î±2a. Journal of the European Academy of Dermatology and Venereology, 1994, 3, 326-330.	2.4	0
184	Laptop dermatitis. Medical Journal of Australia, 2011, 194, 371-371.	1.7	0
185	Sarcoidosis, Hypercalcemia and Calcium-sensing Receptor Mutation: A Case Report. Acta Dermato-Venereologica, 2011, 91, 468-468.	1.3	0
186	Non-evolving linear facial plaque. Clinical and Experimental Dermatology, 2013, 38, 681-683.	1.3	0
187	Deposits of Amyloid (Beta-2 Microglobulin Type) in the Tongue. American Journal of Dermatopathology, 2014, 36, 192-193.	0.6	0
188	Dermatology Over the Rainbow. JAMA Dermatology, 2015, 151, 543.	4.1	0
189	Localized cutaneous immunoglobulin <scp>G</scp>4. International Journal of Dermatology, 2015, 54, 955-958.	1.0	0
190	Cutaneous Side Effects of Single Versus Combined BRAF Inhibitors: A Comment to Erfan et al.. Acta Dermato-Venereologica, 2017, 97, 1267-1268.	1.3	0
191	Pigmentary evolution with pembrolizumab use. British Journal of Dermatology, 2018, 178, 32-33.	1.5	0
192	Do Dermatologic Diagnosis Change in Hot vs Cold Periods of The Year? A Sub-Analysis of the DIADERM National Sample (Spain 2016). Actas Dermo-sifiliogrÃ¡ficas, 2019, 110, 734-743.	0.4	0
193	Incidence of cardiovascular events among tildrakizumab-treated patients with moderate to severe plaque psoriasis: Pooled data from 3 large randomized clinical trials. Journal of the American Academy of Dermatology, 2019, 81, AB79.	1.2	0
194	Increased collaboration between Mohs and plastic surgeons in the surgical management of skin cancer in Australia. Australasian Journal of Dermatology, 2020, 61, 85-87.	0.7	0
195	Mohs Micrographic Surgery in Patients Younger Than 40 Years. Dermatologic Surgery, 2020, 46, 1481-1485.	0.8	0
196	Widespread nodules and papules in a patient with chronic myelomonocytic leukemia. International Journal of Dermatology, 2020, 59, 1071-1072.	1.0	0
197	Rational use of topical corticosteroids. Australian Prescriber, 2014, 37, 5-6.	1.0	0
198	Management of genital hidradenitis suppurativa and lymphoedema with the restoration of erectile function. Australasian Journal of Dermatology, 2022, , .	0.7	0

#	Article	IF	Citations
199	Supine dermoscopy for improved visualisation of lower limb lesions. Dermatology Practical and Conceptual, 0, , e2022065.	0.9	0
200	Cost-effectiveness of targeted genomic risk provision to prevent skin cancer: Results of a randomized trial.. Journal of Clinical Oncology, 2022, 40, 10536-10536.	1.6	0